What is claimed is:

1. An injectable depot formulation comprising:

a solubilized aryl-heterocyclic compound; and a viscosity agent.

2. The injectable depot formulation of Claim 1 wherein said aryl-heterocyclic compound is ziprasidone.

3. The injectable depot formulation of Claim 2 wherein said aryl-heterocyclic compound is solubilized with a cyclodextrin.

4. The injectable depot formulation of Claim 2, optionally comprising a crystallization-inhibitor and wherein said cyclodextrin is present in a concentration of greater than about 50% w/v.

5. The injectable depot formulation of Claim 3, optionally comprising a crystallization-inhibitor and wherein said cyclodextrin is present in a concentration of greater than about 50% w/v.

6. The injectable depot formulation of Claim 2 wherein said viscosity agent comprises a cellulose derivative, polyvinylpyrrolidone, alginates, chitosan, a dextran, gelatin, polyethylene glycols, polyoxyethylene ethers, polyoxypropylene ethers, polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamines, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, polycarbonates, poly(maleic acid), poly(amino acids), polyhydroxycellulose, chitin, copolymers or terpolymers of the foregoing, sucrose acetate isobutyrate, PLGA, stearic acid/NMP, or a combination thereof.

7. The injectable depot formulation of Claim 3 wherein said viscosity agent comprises a cellulose derivative, polyvinylpyrrolidone, alginates, chitosan, a dextran, gelatin, polyethylene glycols, polyoxyethylene ethers, polyoxypropylene ethers, polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamines, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polycarbonates, polyorthocarbonates, polyphosphazenes, succinates, polycarbonates, poly(maleic acid), poly(amino acids), polyhydroxycellulose, chitin, copolymers or terpolymers of the foregoing, sucrose acetate isobutyrate, PLGA, stearic acid/NMP, or a combination thereof.

8. The injectable formulation of Claim 6 wherein said cellulose derivative includes methyl cellulose, sodium carboxymethyl cellulose or hydroxypropyl methyl cellulose, and said polylactides, polyglycolides, copolymers or terploymers thereof includes poly-lactic-co-glycolic acid.

9. The injectable depot formulation of Claim 3 wherein said cyclodextrin is γ-cyclodextrin, β-cyclodextrin, HPBCD, SBECD or a mixture thereof.

10. The injectable depot formulation of Claim 3 wherein said solubilized ziprasidone comprises a pre-formed complex with said cyclodextrin.

11. The injectable depot formulation of Claim 3 further comprising water; optionally a crystallization inhibitor; and a co-solvent comprising a pyrrolidone or mixture of pyrrolidones.

12. The injectable depot formulation of Claim 3 further comprising a non-aqueous polar solvent.

13. The injectable depot formulation of Claim 2 wherein said formulation has a viscosity of greater than about 3.2 cps.

14. The injectable depot formulation of Claim 3 wherein said formulation has a viscosity of greater than about 3.2 cps.

15. A depot formulation for intramuscular injection comprising ziprasidone mesylate solubilized with SBECD; and a viscosity agent.

16. The depot formulation of Claim 15 wherein said SBECD is present at a concentration of from about 5% w/v to about 35% w/v and wherein said viscosity agent is sodium carboxymethyl cellulose in an aqueous vehicle.

17. A depot formulation for intramuscular injection comprising:

ziprasidone mesylate in an amount sufficient to provide at least about 10 mgA to about 30 mgA per day of ziprasidone for at least about 8 hours to about 2 weeks, said ziprasidone mesylate solubilized with SBECD, said SBECD present at a concentration of about 5% to about 35%w/v;

sodium carboxymethyl cellulose present in a concentration of about 0.25% w/v to about 2% w/v;

optionally a pharmaceutically acceptable surfactant present in an amount of up to about 1%; and

water.

18. A method of treating a psychotic disorder, for example schizophrenia comprising:

administering by intramuscular injection to a patient in need of such treatment a depot formulation comprised of ziprasidone in an amount sufficient to provide at least about 10 mgA to about 30 mgA per day of said ziprasidone for at least about 8 hours to about 2 weeks, said ziprasidone solubilized with SBECD, said formulation further comprising a viscosity agent.